text: San Francisco /PRNewswire/ - Arterys Inc., the leader in intelligent, cloud-based medical imaging software solutions, recently announced its fifth 510(k) clearance from the U.S. Food and Drug Administration (FDA). The clearance is for the Arterys Oncology AI suite, and is a milestone indicative of the company's momentum in applying AI to advance medical imaging accuracy and consistency.
  The company's goal is to reduce variability and subjectivity in the clinical diagnoses, and alleviate the enormous workloads radiologists face. With AI, the company is improving the accuracy and consistency in imaging interpretation across practices. Arterys is now focused on expanding its technology beyond cardiac MRI to continue expanding its offering by solving some of radiologists' most pressing needs. For more information, please contact us at www.arterys.com.